160 related articles for article (PubMed ID: 30945098)
1. Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.
van Oosterom N; Winckel K; Barras M
J Thromb Thrombolysis; 2019 Oct; 48(3):387-393. PubMed ID: 30945098
[TBL] [Abstract][Full Text] [Related]
2. Impact of Weight on Anti-Xa Attainment in High-Risk Trauma Patients on Enoxaparin Chemoprophylaxis.
Farrar JE; Droege ME; Philpott CD; Mueller EW; Ernst NE; Makley AT; Deichstetter KM; Droege CA
J Surg Res; 2021 Aug; 264():425-434. PubMed ID: 33848842
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
[TBL] [Abstract][Full Text] [Related]
4. Enoxaparin dosing after cesarean delivery in morbidly obese women.
Overcash RT; Somers AT; LaCoursiere DY
Obstet Gynecol; 2015 Jun; 125(6):1371-1376. PubMed ID: 26000508
[TBL] [Abstract][Full Text] [Related]
5. Enoxaparin dosing in the elderly using adjusted body weight.
Leri F; Voyce SJ; Scialla S; Glavich W; Dzielak E; Smego RA; Guzek J
J Thromb Thrombolysis; 2009 Oct; 28(3):348-53. PubMed ID: 19283449
[TBL] [Abstract][Full Text] [Related]
6. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
7. Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient.
Rahawi KW; Higgins KL; Noda C; Stultz JS
Pharmacotherapy; 2017 Apr; 37(4):e16-e20. PubMed ID: 28152224
[TBL] [Abstract][Full Text] [Related]
8. Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study.
Lee YR; Palmere PJ; Burton CE; Benavides TM
Clin Drug Investig; 2020 Jan; 40(1):33-40. PubMed ID: 31625111
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of anti-factor Xa concentrations using a body mass index-based enoxaparin dosing protocol for venous thromboembolism prophylaxis in trauma patients.
O'Keefe MM; Carver TW; Herrmann DJ; Prom A; Hubbard S; Rein LE; Peppard WJ
Pharmacotherapy; 2022 Mar; 42(3):216-223. PubMed ID: 35100448
[TBL] [Abstract][Full Text] [Related]
10. Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.
Thompson-Moore NR; Wanat MA; Putney DR; Liebl PH; Chandler WL; Muntz JE
Clin Appl Thromb Hemost; 2015 Sep; 21(6):513-20. PubMed ID: 25601898
[TBL] [Abstract][Full Text] [Related]
11. Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting.
Rodier SG; Bukur M; Moore S; Frangos SG; Tandon M; DiMaggio CJ; Ayoung-Chee P; Marshall GT
Eur J Trauma Emerg Surg; 2021 Feb; 47(1):145-151. PubMed ID: 31471669
[TBL] [Abstract][Full Text] [Related]
12. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
Lee YR; Vega JA; Duong HN; Ballew A
Pharmacotherapy; 2015 Nov; 35(11):1007-15. PubMed ID: 26598093
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.
Stephenson ML; Serra AE; Neeper JM; Caballero DC; McNulty J
J Perinatol; 2016 Feb; 36(2):95-9. PubMed ID: 26658126
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series.
Deal EN; Hollands JM; Riney JN; Skrupky LP; Smith JR; Reichley RM
J Thromb Thrombolysis; 2011 Aug; 32(2):188-94. PubMed ID: 21465129
[TBL] [Abstract][Full Text] [Related]
15. Assessing an enoxaparin dosing protocol in morbidly obese patients.
Lalama JT; Feeney ME; Vandiver JW; Beavers KD; Walter LN; McClintic JR
J Thromb Thrombolysis; 2015 May; 39(4):516-21. PubMed ID: 25087072
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of therapeutic enoxaparin dosing in obesity.
Chilbert MR; Zammit K; Ahmed U; Devlin A; Radparvar S; Schuler A; Woodruff AE
J Thromb Thrombolysis; 2024 Apr; 57(4):587-597. PubMed ID: 38402505
[TBL] [Abstract][Full Text] [Related]
17. Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study.
Miranda S; Le Cam-Duchez V; Benichou J; Donnadieu N; Barbay V; Le Besnerais M; Delmas FX; Cuvelier A; Lévesque H; Benhamou Y; Armengol G
Thromb Res; 2017 Jul; 155():1-5. PubMed ID: 28460259
[TBL] [Abstract][Full Text] [Related]
18. Individualized dosing of enoxaparin in a morbidly obese patient by monitoring the anti-factor Xa.
Mazhar F; Ahmed Y
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):169-170. PubMed ID: 27936527
[No Abstract] [Full Text] [Related]
19. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
[TBL] [Abstract][Full Text] [Related]
20. Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels.
Ebied AM; Li T; Axelrod SF; Tam DJ; Chen Y
J Thromb Thrombolysis; 2020 Feb; 49(2):206-213. PubMed ID: 31486963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
